Eyegate Pharmaceuticals, Inc. (EYEG) EPS Estimated At $-0.26

February 13, 2018 - By Kenneth Lin

 Eyegate Pharmaceuticals, Inc. (EYEG) EPS Estimated At $ 0.26

Analysts expect Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) to report $-0.26 EPS on February, 22.They anticipate $0.12 EPS change or 31.58 % from last quarter’s $-0.38 EPS. After having $-0.24 EPS previously, Eyegate Pharmaceuticals, Inc.’s analysts see 8.33 % EPS growth. The stock decreased 2.81% or $0.02 during the last trading session, reaching $0.67. About 95,601 shares traded. Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) has declined 40.33% since February 14, 2017 and is downtrending. It has underperformed by 57.03% the S&P500.

Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) Ratings Coverage

Among 2 analysts covering Eyegate Pharmaceuticals (NASDAQ:EYEG), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Eyegate Pharmaceuticals had 2 analyst reports since November 12, 2015 according to SRatingsIntel. The stock of Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) has “Buy” rating given on Thursday, November 12 by Maxim Group. Chardan Capital Markets initiated the shares of EYEG in report on Wednesday, December 23 with “Buy” rating.

EyeGate Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing drug compositions and drug delivery systems for treating diseases and disorders of the eye. The company has market cap of $11.54 million. The firm is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including the treatment of ocular inflammation and pain in post-surgical cataract patients; and uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea. It currently has negative earnings. It is also developing the EyeGate Ocular Bandage Gel, a topically-applied eye drop formulation that has completed its first-in-man clinical trial for the management of corneal epithelial defects, as well as to accelerate re-epithelization of the ocular surface following surgery, injection, and other traumatic and non-traumatic conditions.

More notable recent Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) news were published by: Streetinsider.com which released: “Eyegate Pharma (EYEG) Announces Promotion of Sarah Romano to CFO Position” on January 04, 2018, also Globenewswire.com with their article: “EyeGate to Present at the 2018 BIO CEO & Investor Conference” published on February 07, 2018, Streetinsider.com published: “Eyegate Pharma (EYEG) Reports New US Patent for Iontophoretic Delivery of …” on December 19, 2017. More interesting news about Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) were released by: Globenewswire.com and their article: “EyeGate Announces Top-Line Results for Phase 2b Trial of EGP-437 in Cataract …” published on February 05, 2018 as well as Globenewswire.com‘s news article titled: “EyeGate Pharma Enrolls First Patient in Phase 2b Clinical Study of EGP-437 for …” with publication date: August 01, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: